Patent ID: 9492432
Filing Date: 2016-11-15
CPC Classification: A61B,A61F,A61K,A61P

Claim Text:
1. A method of preserving visual function of an eye of a subject with an ocular condition selected from the group consisting of retinal detachment, age-related macular degeneration and retinitis pigmentosa, wherein a symptom of the ocular condition is the loss of photoreceptor cell viability in the retina of the eye with the condition, the method comprising: (a) administering to the eye of the subject an effective amount of a necrostatin and an effective amount of an apoptosis inhibitor selected from the group consisting of a pan-caspase inhibitor, a caspase-1 inhibitor, a caspase-3 inhibitor, a caspase-8 inhibitor, and a caspase-9 inhibitor thereby to preserve the viability of photoreceptor cells disposed within the retina of the eye; and (b) after step (a), measuring visual function of the eye; wherein the necrostatin is selected from the group consisting of: (i) a Nec-1 related compound of Formula I: or a pharmaceutically acceptable salt, ester, or prodrug thereof, wherein X is O or S; R R (ii) a Nec-1 related compound of Formula I-A: or a pharmaceutically acceptable salt, ester, or prodrug thereof, wherein R (iii) a Nec-1 related compound of Formula I-B: or a pharmaceutically acceptable salt, ester, or prodrug thereof; (iv) a Nec-1 related compound of Formula I-C or a pharmaceutically acceptable salt, ester, or prodrug thereof; (v) a Nec-1 related compound of Formula I-D or a pharmaceutically acceptable salt thereof; (vi) a Nec-1 related compound of Formula I-E: or a pharmaceutically acceptable salt, ester, or prodrug thereof, wherein R (vii) a Nec-2 related compound of Formula II: or a pharmaceutically acceptable salt, ester, or prodrug thereof, wherein: X is —CH R R R R the bond indicated by (a) can be a single or double bond; and the bond indicated by (b) can be a single or double bond; (viii) a Nec-2 related compound of Formula II-A: or a pharmaceutically acceptable salt thereof, wherein: R R (ix) a Nec-3 related compound of Formula III: or a pharmaceutically acceptable salt, ester, or prodrug thereof, wherein: Z is —CH R R R R R n represents independently for each occurrence 0, 1, or 2; (x) a Nec-4 related compound of Formula IV: or a pharmaceutically acceptable salt, ester, or prodrug thereof, wherein: R R R R R R R A is phenylene or a 5-6 membered heteroarylene; X is N or —C(R Y is N or —C(R Z is S or O; and m and n each represent independently 1, 2, or 3; (xi) a Nec-5 related compound of Formula V: or a pharmaceutically acceptable salt, ester, or prodrug thereof, wherein: X is a bond or C R R or R R R B is a 5-6 membered heterocyclic or carbocylic ring; and n and p each represent independently 0, 1, or 2; (xii) a Nec-5 related compound of Formula V-A: R or R R R B is a 5-6 membered heterocyclic or carbocylic ring; and n and p each represent independently 0, 1, or 2; (xiii) a Nec-7 related compound of Formula VII: or a pharmaceutically acceptable salt, ester, or prodrug thereof, wherein: R R or R R A is a 5-6 membered heterocyclic ring; and p is 0, 1, or 2; (xiv) a Nec-7 related compound of Formula VIII: or a pharmaceutically acceptable salt, ester, or prodrug thereof, wherein: each X each Y each Z each R each R each R each R (xv) a Nec-4 related compound of Formula IX: or a pharmaceutically acceptable salt, ester, or prodrug thereof, wherein: X X Y is selected from C(O) or CH Z is (CR R R R each R R each R n is 0, 1, 2, or 3.